The Jules Bordet Institute and IBA lead the IHI project “Accelerate.EU”

Hugo Levillain shared a post on LinkedIn by The Brussels University Hospital, adding:

“Exciting News! The Jules Bordet Institute and IBA are proud to lead the IHI project ‘Accelerate.EU’—a groundbreaking €16 million initiative aimed at establishing a complete Astatine-211 value chain, advancing Europe’s strategic autonomy in alpha therapies for cancer.

I’m truly honored to serve as the project lead coordinator for this fantastic initiative, which also marks the first European project coordinated by the Jules Bordet Institute.

This project is a unique opportunity to:

• Strengthen IJB’s expertise in managing large-scale European projects
• Solidify IJB’s position as a global reference center in theranostics

Accelerate.EU will focus on developing innovative radiopharmaceutical treatments using Astatine-211 to address critical unmet clinical needs in triple-negative breast cancer, pancreatic cancer, and glioblastoma.

Key contributions from IJB include:

• Preclinical characterization of radiopharmaceuticals like 211At-NTR1 for pancreatic cancer and 211At-dualFAPi for triple-negative breast cancer
• Sponsoring a Phase 1 bicentric study with the Institut de Cancérologie de l’Ouest (ICO) in Nantes, France, on 211At-dualFAPi for triple-negative breast cancer
• Collaborating with SCK-CEN and ICO to conduct the world’s first co-clinical radiotherapeutic study on 211At-dualFAPi for triple-negative breast cancer

This achievement would not have been possible without strong, multidisciplinary teamwork. A huge thank you to all contributing partners and our local dream team: Patrick Flamen, Wendy Delbart, Geraldine Gebhart, Magdalena Mileva, Loubna T., Zena Wimana, Marielle Sautois, Julie Gaye, Helena De Stobbeleir, Martin K. Smith, Francis de Drée.

A special thanks to the Innovative Health Initiative (IHI) for their invaluable support.

Excited to continue driving innovation and improving outcomes for cancer patients across Europe. Stay tuned for more updates!”

Quoting The Brussels University Hospital’s post:

“It is with great pride that The Jules Bordet Institute will participate in the study ‘Accelerate.EU’

This ambitious project aims to improve patient access to innovative cancer treatments.

Associated with 17 partners, the Jules Bordet Institute and IBA will coordinate this project, which will transform cancer care by promoting the development of new radiotherapeutic solutions.

We can’t wait to start this project and announce our innovations, in the meantime, discover all the information about this project in this press release.”

Read further.
Sources: Hugo Levillain/LinkedIn and The Brussels University Hospital/LinkedIn

Hugo Levillain is the Head of Research and Development in the Medical Physics Department at the Institut Jules Bordet. He also leads the NuMix project at the Center for Microscopy and Molecular Imaging (CMMI). Additionally, he holds a position as a university lecturer at Free University of Brussels.